ID   CP4F2_HUMAN             Reviewed;         520 AA.
AC   P78329; A0A024R7K3; A8K425; B4DV75; Q16677; Q6NWT4; Q6NWT6; Q9NNZ0;
AC   Q9UIU8;
DT   15-DEC-1998, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1997, sequence version 1.
DT   10-MAY-2017, entry version 167.
DE   RecName: Full=Phylloquinone omega-hydroxylase CYP4F2 {ECO:0000305};
DE            EC=1.14.13.194 {ECO:0000269|PubMed:24138531};
DE   AltName: Full=20-hydroxyeicosatetraenoic acid synthase {ECO:0000303|PubMed:10660572};
DE            Short=20-HETE synthase {ECO:0000303|PubMed:10660572};
DE            EC=1.14.13.- {ECO:0000269|PubMed:10660572};
DE   AltName: Full=Arachidonic acid omega-hydroxylase {ECO:0000303|PubMed:10660572};
DE   AltName: Full=CYPIVF2;
DE   AltName: Full=Cytochrome P450 4F2;
DE   AltName: Full=Cytochrome P450-LTB-omega;
DE   AltName: Full=Leukotriene-B(4) 20-monooxygenase 1;
DE   AltName: Full=Leukotriene-B(4) omega-hydroxylase 1 {ECO:0000305};
DE            EC=1.14.13.30 {ECO:0000269|PubMed:8026587, ECO:0000269|PubMed:9799565};
DE   Flags: Precursor;
GN   Name=CYP4F2 {ECO:0000312|HGNC:HGNC:2645};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY,
RP   AND SUBCELLULAR LOCATION.
RC   TISSUE=Liver;
RX   PubMed=8026587; DOI=10.1016/0014-5793(94)00587-7;
RA   Kikuta Y., Kusunose E., Kondo T., Yamamoto S., Kinoshita H.,
RA   Kusunose M.;
RT   "Cloning and expression of a novel form of leukotriene B4 omega-
RT   hydroxylase from human liver.";
RL   FEBS Lett. 348:70-74(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND TISSUE SPECIFICITY.
RX   PubMed=10492403; DOI=10.1089/104454999315006;
RA   Kikuta Y., Miyauchi Y., Kusunose E., Kusunose M.;
RT   "Expression and molecular cloning of human liver leukotriene B4 omega-
RT   hydroxylase (CYP4F2) gene.";
RL   DNA Cell Biol. 18:723-730(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RA   Chen L., Hardwick J.P.;
RT   "The human liver CYP4F2 cDNA sequence and expression in baculovirus-
RT   infected insect cells.";
RL   Submitted (JUL-2000) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   VAL-185.
RC   TISSUE=Kidney, and Small intestine;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS TYR-7; GLY-12;
RP   VAL-185; MET-433 AND MET-519.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JAN-2002) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS
RP   GLY-12 AND MET-433.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-175.
RC   TISSUE=Liver;
RX   PubMed=10860554; DOI=10.1006/abbi.2000.1836;
RA   Zhang X., Chen L., Hardwick J.P.;
RT   "Promoter activity and regulation of the CYP4F2 leukotriene B4 omega
RT   hydroxylase gene by peroxisomal proliferators and retinoic acid in
RT   HepG2 cells.";
RL   Arch. Biochem. Biophys. 378:364-376(2000).
RN   [10]
RP   PROTEIN SEQUENCE OF 5-21, FUNCTION, CATALYTIC ACTIVITY,
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND VARIANT GLY-12.
RX   PubMed=9799565; DOI=10.1006/abbi.1998.0880;
RA   Jin R., Koop D.R., Raucy J.L., Lasker J.M.;
RT   "Role of human CYP4F2 in hepatic catabolism of the proinflammatory
RT   agent leukotriene B4.";
RL   Arch. Biochem. Biophys. 359:89-98(1998).
RN   [11]
RP   FUNCTION, CATALYTIC ACTIVITY, AND TISSUE SPECIFICITY.
RX   PubMed=10660572; DOI=10.1074/jbc.275.6.4118;
RA   Lasker J.M., Chen W.B., Wolf I., Bloswick B.P., Wilson P.D.,
RA   Powell P.K.;
RT   "Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and
RT   natriuretic eicosanoid, in human kidney. Role of Cyp4F2 and Cyp4A11.";
RL   J. Biol. Chem. 275:4118-4126(2000).
RN   [12]
RP   FUNCTION, AND CHARACTERIZATION OF VARIANT MET-433.
RX   PubMed=17341693; DOI=10.1152/physiolgenomics.00003.2007;
RA   Stec D.E., Roman R.J., Flasch A., Rieder M.J.;
RT   "Functional polymorphism in human CYP4F2 decreases 20-HETE
RT   production.";
RL   Physiol. Genomics 30:74-81(2007).
RN   [13]
RP   FUNCTION, AND CHARACTERIZATION OF VARIANT MET-433.
RX   PubMed=18574070; DOI=10.1161/HYPERTENSIONAHA.108.114199;
RA   Fava C., Montagnana M., Almgren P., Rosberg L., Lippi G., Hedblad B.,
RA   Engstrom G., Berglund G., Minuz P., Melander O.;
RT   "The V433M variant of the CYP4F2 is associated with ischemic stroke in
RT   male Swedes beyond its effect on blood pressure.";
RL   Hypertension 52:373-380(2008).
RN   [14]
RP   INVOLVEMENT IN CMRES, AND CHARACTERIZATION OF VARIANT MET-433.
RX   PubMed=18250228; DOI=10.1182/blood-2007-11-122010;
RA   Caldwell M.D., Awad T., Johnson J.A., Gage B.F., Falkowski M.,
RA   Gardina P., Hubbard J., Turpaz Y., Langaee T.Y., Eby C., King C.R.,
RA   Brower A., Schmelzer J.R., Glurich I., Vidaillet H.J., Yale S.H.,
RA   Qi Zhang K., Berg R.L., Burmester J.K.;
RT   "CYP4F2 genetic variant alters required warfarin dose.";
RL   Blood 111:4106-4112(2008).
RN   [15]
RP   INVOLVEMENT IN CMRES, AND CHARACTERIZATION OF VARIANT MET-433.
RX   PubMed=19270263; DOI=10.1182/blood-2008-09-176222;
RA   Perez-Andreu V., Roldan V., Anton A.I., Garcia-Barbera N., Corral J.,
RA   Vicente V., Gonzalez-Conejero R.;
RT   "Pharmacogenetic relevance of CYP4F2 V433M polymorphism on
RT   acenocoumarol therapy.";
RL   Blood 113:4977-4979(2009).
RN   [16]
RP   FUNCTION, SUBCELLULAR LOCATION, INVOLVEMENT IN CMRES, AND
RP   CHARACTERIZATION OF VARIANT MET-433.
RX   PubMed=19297519; DOI=10.1124/mol.109.054833;
RA   McDonald M.G., Rieder M.J., Nakano M., Hsia C.K., Rettie A.E.;
RT   "CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin
RT   dose in carriers of the V433M variant.";
RL   Mol. Pharmacol. 75:1337-1346(2009).
RN   [17]
RP   INVOLVEMENT IN CMRES, AND CHARACTERIZATION OF VARIANT MET-433.
RX   PubMed=19207028; DOI=10.2217/14622416.10.2.261;
RA   Borgiani P., Ciccacci C., Forte V., Sirianni E., Novelli L.,
RA   Bramanti P., Novelli G.;
RT   "CYP4F2 genetic variant (rs2108622) significantly contributes to
RT   warfarin dosing variability in the Italian population.";
RL   Pharmacogenomics 10:261-266(2009).
RN   [18]
RP   INVOLVEMENT IN CMRES, AND CHARACTERIZATION OF VARIANT MET-433.
RX   PubMed=20555338; DOI=10.1038/jhg.2010.73;
RA   Ross K.A., Bigham A.W., Edwards M., Gozdzik A., Suarez-Kurtz G.,
RA   Parra E.J.;
RT   "Worldwide allele frequency distribution of four polymorphisms
RT   associated with warfarin dose requirements.";
RL   J. Hum. Genet. 55:582-589(2010).
RN   [19]
RP   SUBCELLULAR LOCATION.
RX   PubMed=20861217; DOI=10.3945/jn.110.128579;
RA   Bardowell S.A., Stec D.E., Parker R.S.;
RT   "Common variants of cytochrome P450 4F2 exhibit altered vitamin
RT   E-{omega}-hydroxylase specific activity.";
RL   J. Nutr. 140:1901-1906(2010).
RN   [20]
RP   INVOLVEMENT IN CMRES, AND CHARACTERIZATION OF VARIANT MET-433.
RX   PubMed=23132553; DOI=10.1038/clpt.2012.184;
RA   Danese E., Montagnana M., Johnson J.A., Rettie A.E., Zambon C.F.,
RA   Lubitz S.A., Suarez-Kurtz G., Cavallari L.H., Zhao L., Huang M.,
RA   Nakamura Y., Mushiroda T., Kringen M.K., Borgiani P., Ciccacci C.,
RA   Au N.T., Langaee T., Siguret V., Loriot M.A., Sagreiya H.,
RA   Altman R.B., Shahin M.H., Scott S.A., Khalifa S.I., Chowbay B.,
RA   Suriapranata I.M., Teichert M., Stricker B.H., Taljaard M.,
RA   Botton M.R., Zhang J.E., Pirmohamed M., Zhang X., Carlquist J.F.,
RA   Horne B.D., Lee M.T., Pengo V., Guidi G.C., Minuz P., Fava C.;
RT   "Impact of the CYP4F2 p.V433M polymorphism on coumarin dose
RT   requirement: systematic review and meta-analysis.";
RL   Clin. Pharmacol. Ther. 92:746-756(2012).
RN   [21]
RP   FUNCTION, SUBCELLULAR LOCATION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL
RP   PROPERTIES, INVOLVEMENT IN CMRES, IDENTIFICATION BY MASS SPECTROMETRY,
RP   AND PATHWAY.
RX   PubMed=24138531; DOI=10.1021/bi401208m;
RA   Edson K.Z., Prasad B., Unadkat J.D., Suhara Y., Okano T.,
RA   Guengerich F.P., Rettie A.E.;
RT   "Cytochrome P450-dependent catabolism of vitamin K: omega-
RT   hydroxylation catalyzed by human CYP4F2 and CYP4F11.";
RL   Biochemistry 52:8276-8285(2013).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
CC   -!- FUNCTION: Omega-hydroxylase that oxidizes a variety of
CC       structurally unrelated compounds, including steroids, fatty acids
CC       and xenobiotics. Plays a key role in vitamin K catabolism by
CC       mediating omega-hydroxylation of vitamin K1 (phylloquinone), and
CC       menaquinone-4 (MK-4), a form of vitamin K2. Hydroxylation of
CC       phylloquinone and MK-4 probably regulates blood coagulation
CC       (PubMed:19297519, PubMed:24138531). Also shows arachidonic acid
CC       omega-hydroxylase activity in kidney, by mediating conversion of
CC       arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE),
CC       possibly influencing blood pressure control (PubMed:10660572,
CC       PubMed:17341693, PubMed:18574070). Also acts as a leukotriene-B(4)
CC       omega-hydroxylase by mediating conversion of leukotriene-B(4)
CC       (LTB4) to its omega-hydroxylated metabolite 20-hydroxyleukotriene-
CC       B(4) (20-OH LTB4) (PubMed:8026587, PubMed:9799565).
CC       {ECO:0000269|PubMed:10660572, ECO:0000269|PubMed:17341693,
CC       ECO:0000269|PubMed:18574070, ECO:0000269|PubMed:19297519,
CC       ECO:0000269|PubMed:24138531, ECO:0000269|PubMed:8026587,
CC       ECO:0000269|PubMed:9799565}.
CC   -!- CATALYTIC ACTIVITY: (6Z,8E,10E,14Z)-(5S,12R)-5,12-dihydroxyicosa-
CC       6,8,10,14-tetraenoate + NADPH + O(2) = (6Z,8E,10E,14Z)-(5S,12R)-
CC       5,12,20-trihydroxyicosa-6,8,10,14-tetraenoate + NADP(+) + H(2)O.
CC       {ECO:0000269|PubMed:8026587, ECO:0000269|PubMed:9799565}.
CC   -!- CATALYTIC ACTIVITY: Phylloquinone + NADPH + O(2) = omega-
CC       hydroxyphylloquinone + NADP(+) + H(2)O.
CC       {ECO:0000269|PubMed:24138531}.
CC   -!- CATALYTIC ACTIVITY: (5Z,8Z,11Z,14Z)-icosatetraenoate + NADPH +
CC       O(2) = (5Z,8Z,11Z,14Z)-20-hydroxyicosa-5,8,11,14-tetraenoate +
CC       NADP(+) + H(2)O. {ECO:0000269|PubMed:10660572}.
CC   -!- COFACTOR:
CC       Name=heme; Xref=ChEBI:CHEBI:30413;
CC         Evidence={ECO:0000250|UniProtKB:P24464};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=74.8 uM for leukotriene-B(4) {ECO:0000269|PubMed:9799565};
CC         KM=1.7 uM for menaquinone-4 (MK-4)
CC         {ECO:0000269|PubMed:24138531};
CC         Vmax=2.42 nmol/min/mg enzyme {ECO:0000269|PubMed:9799565};
CC         Note=kcat is 0.067 min(-1) with menaquinone-4 (MK-4) as
CC         substrate. {ECO:0000269|PubMed:24138531};
CC   -!- PATHWAY: Cofactor degradation; phylloquinone degradation.
CC       {ECO:0000269|PubMed:24138531}.
CC   -!- INTERACTION:
CC       O43889-2:CREB3; NbExp=3; IntAct=EBI-1752413, EBI-625022;
CC       P16333:NCK1; NbExp=2; IntAct=EBI-1752413, EBI-389883;
CC   -!- SUBCELLULAR LOCATION: Microsome membrane
CC       {ECO:0000269|PubMed:19297519, ECO:0000269|PubMed:24138531,
CC       ECO:0000269|PubMed:8026587}; Peripheral membrane protein
CC       {ECO:0000305}. Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:20861217}; Peripheral membrane protein
CC       {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P78329-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P78329-2; Sequence=VSP_055578, VSP_055579, VSP_055580;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Liver. Also present in kidney: specifically
CC       expressed in the S2 and S3 segments of proximal tubules in cortex
CC       and outer medulla (PubMed:10660572). {ECO:0000269|PubMed:10492403,
CC       ECO:0000269|PubMed:10660572}.
CC   -!- DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition
CC       characterized by partial or complete resistance to warfarin or
CC       other 4-hydroxycoumarin derivatives. These drugs are used as anti-
CC       coagulants for the prevention of thromboembolic diseases in
CC       subjects with deep vein thrombosis, atrial fibrillation, or
CC       mechanical heart valve replacement. {ECO:0000269|PubMed:18250228,
CC       ECO:0000269|PubMed:19207028, ECO:0000269|PubMed:19270263,
CC       ECO:0000269|PubMed:19297519, ECO:0000269|PubMed:20555338,
CC       ECO:0000269|PubMed:23132553, ECO:0000269|PubMed:24138531}.
CC       Note=Disease susceptibility may be associated with variations
CC       affecting the gene represented in this entry. The variant Met-433
CC       is associated with coumarin (the brand name of warfarin)
CC       resistance by increasing coumarin maintenance dose in patients on
CC       this anti-coagulant therapy. This is probably due to decreased
CC       activity of the phylloquinone omega-hydroxylase activity, leading
CC       to an increase in hepatic vitamin K levels that warfarin must
CC       antagonize (PubMed:24138531). {ECO:0000269|PubMed:24138531}.
CC   -!- SIMILARITY: Belongs to the cytochrome P450 family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/cyp4f2/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D26480; BAA05490.1; -; mRNA.
DR   EMBL; AB015306; BAA75823.1; -; Genomic_DNA.
DR   EMBL; U02388; AAC50052.2; -; mRNA.
DR   EMBL; AK290790; BAF83479.1; -; mRNA.
DR   EMBL; AK300961; BAG62587.1; -; mRNA.
DR   EMBL; AF467894; AAL67578.1; -; Genomic_DNA.
DR   EMBL; AC005336; AAC27730.1; -; Genomic_DNA.
DR   EMBL; AC004791; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471106; EAW84509.1; -; Genomic_DNA.
DR   EMBL; CH471106; EAW84510.1; -; Genomic_DNA.
DR   EMBL; BC067437; AAH67437.1; -; mRNA.
DR   EMBL; BC067439; AAH67439.1; -; mRNA.
DR   EMBL; BC067440; AAH67440.1; -; mRNA.
DR   EMBL; AF221943; AAF86378.1; -; Genomic_DNA.
DR   CCDS; CCDS12336.1; -. [P78329-1]
DR   PIR; S45702; S45702.
DR   RefSeq; NP_001073.3; NM_001082.4. [P78329-1]
DR   UniGene; Hs.558423; -.
DR   ProteinModelPortal; P78329; -.
DR   SMR; P78329; -.
DR   BioGrid; 114099; 2.
DR   IntAct; P78329; 6.
DR   STRING; 9606.ENSP00000221700; -.
DR   BindingDB; P78329; -.
DR   ChEMBL; CHEMBL3379; -.
DR   DrugBank; DB08868; Fingolimod.
DR   DrugBank; DB09148; Florbetaben (18F).
DR   GuidetoPHARMACOLOGY; 1344; -.
DR   SwissLipids; SLP:000000421; -.
DR   iPTMnet; P78329; -.
DR   PhosphoSitePlus; P78329; -.
DR   BioMuta; CYP4F2; -.
DR   DMDM; 6166044; -.
DR   MaxQB; P78329; -.
DR   PaxDb; P78329; -.
DR   PeptideAtlas; P78329; -.
DR   PRIDE; P78329; -.
DR   Ensembl; ENST00000221700; ENSP00000221700; ENSG00000186115. [P78329-1]
DR   GeneID; 8529; -.
DR   KEGG; hsa:8529; -.
DR   UCSC; uc002nbs.2; human. [P78329-1]
DR   CTD; 8529; -.
DR   DisGeNET; 8529; -.
DR   GeneCards; CYP4F2; -.
DR   HGNC; HGNC:2645; CYP4F2.
DR   HPA; HPA014048; -.
DR   HPA; HPA058960; -.
DR   MalaCards; CYP4F2; -.
DR   MIM; 122700; phenotype.
DR   MIM; 604426; gene.
DR   neXtProt; NX_P78329; -.
DR   OpenTargets; ENSG00000186115; -.
DR   Orphanet; 413674; Vitamin K antagonists toxicity or dose selection.
DR   PharmGKB; PA27121; -.
DR   eggNOG; KOG0157; Eukaryota.
DR   eggNOG; COG2124; LUCA.
DR   GeneTree; ENSGT00760000118816; -.
DR   HOVERGEN; HBG000182; -.
DR   InParanoid; P78329; -.
DR   KO; K17726; -.
DR   OMA; HPENIKE; -.
DR   PhylomeDB; P78329; -.
DR   TreeFam; TF105088; -.
DR   BioCyc; MetaCyc:HS02675-MONOMER; -.
DR   BRENDA; 1.14.13.30; 2681.
DR   Reactome; R-HSA-211935; Fatty acids.
DR   Reactome; R-HSA-211958; Miscellaneous substrates.
DR   Reactome; R-HSA-211979; Eicosanoids.
DR   Reactome; R-HSA-2142691; Synthesis of Leukotrienes (LT) and Eoxins (EX).
DR   Reactome; R-HSA-2142816; Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE).
DR   UniPathway; UPA01054; -.
DR   GeneWiki; CYP4F2; -.
DR   GenomeRNAi; 8529; -.
DR   PRO; PR:P78329; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000186115; -.
DR   CleanEx; HS_CYP4F2; -.
DR   ExpressionAtlas; P78329; baseline and differential.
DR   Genevisible; P78329; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:UniProtKB.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:UniProtKB.
DR   GO; GO:0031090; C:organelle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0097259; F:20-aldehyde-leukotriene B4 20-monooxygenase activity; TAS:Reactome.
DR   GO; GO:0097258; F:20-hydroxy-leukotriene B4 omega oxidase activity; TAS:Reactome.
DR   GO; GO:0018685; F:alkane 1-monooxygenase activity; IDA:BHF-UCL.
DR   GO; GO:0052871; F:alpha-tocopherol omega-hydroxylase activity; IDA:UniProtKB.
DR   GO; GO:0008392; F:arachidonic acid epoxygenase activity; IDA:UniProtKB.
DR   GO; GO:0052869; F:arachidonic acid omega-hydroxylase activity; IDA:UniProtKB.
DR   GO; GO:0020037; F:heme binding; IEA:InterPro.
DR   GO; GO:0005506; F:iron ion binding; IEA:InterPro.
DR   GO; GO:0050051; F:leukotriene-B4 20-monooxygenase activity; IDA:UniProtKB.
DR   GO; GO:0004497; F:monooxygenase activity; TAS:Reactome.
DR   GO; GO:0016709; F:oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen; IDA:UniProtKB.
DR   GO; GO:0052872; F:tocotrienol omega-hydroxylase activity; IDA:UniProtKB.
DR   GO; GO:0019369; P:arachidonic acid metabolic process; IDA:UniProtKB.
DR   GO; GO:0007596; P:blood coagulation; TAS:UniProtKB.
DR   GO; GO:0017144; P:drug metabolic process; IMP:UniProtKB.
DR   GO; GO:0019373; P:epoxygenase P450 pathway; IDA:UniProtKB.
DR   GO; GO:0006690; P:icosanoid metabolic process; TAS:Reactome.
DR   GO; GO:0036101; P:leukotriene B4 catabolic process; IDA:UniProtKB.
DR   GO; GO:0006691; P:leukotriene metabolic process; TAS:Reactome.
DR   GO; GO:0001676; P:long-chain fatty acid metabolic process; IDA:BHF-UCL.
DR   GO; GO:0042361; P:menaquinone catabolic process; IDA:UniProtKB.
DR   GO; GO:0032304; P:negative regulation of icosanoid secretion; IMP:UniProtKB.
DR   GO; GO:0097267; P:omega-hydroxylase P450 pathway; TAS:Reactome.
DR   GO; GO:0055114; P:oxidation-reduction process; IDA:UniProtKB.
DR   GO; GO:0042376; P:phylloquinone catabolic process; IDA:UniProtKB.
DR   GO; GO:0032305; P:positive regulation of icosanoid secretion; IMP:UniProtKB.
DR   GO; GO:0003095; P:pressure natriuresis; IEP:UniProtKB.
DR   GO; GO:0008217; P:regulation of blood pressure; IMP:UniProtKB.
DR   GO; GO:0003091; P:renal water homeostasis; IEP:UniProtKB.
DR   GO; GO:0055078; P:sodium ion homeostasis; IEP:UniProtKB.
DR   GO; GO:0000038; P:very long-chain fatty acid metabolic process; IDA:BHF-UCL.
DR   GO; GO:0042360; P:vitamin E metabolic process; IDA:UniProtKB.
DR   GO; GO:0042377; P:vitamin K catabolic process; IDA:UniProtKB.
DR   InterPro; IPR001128; Cyt_P450.
DR   InterPro; IPR017972; Cyt_P450_CS.
DR   InterPro; IPR002401; Cyt_P450_E_grp-I.
DR   Pfam; PF00067; p450; 1.
DR   PRINTS; PR00463; EP450I.
DR   PRINTS; PR00385; P450.
DR   SUPFAM; SSF48264; SSF48264; 1.
DR   PROSITE; PS00086; CYTOCHROME_P450; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Complete proteome; Direct protein sequencing;
KW   Endoplasmic reticulum; Heme; Iron; Membrane; Metal-binding; Microsome;
KW   Monooxygenase; NADP; Oxidoreductase; Polymorphism; Reference proteome.
FT   PROPEP        1      4       {ECO:0000269|PubMed:9799565}.
FT                                /FTId=PRO_0000430581.
FT   CHAIN         5    520       Phylloquinone omega-hydroxylase CYP4F2.
FT                                /FTId=PRO_0000051850.
FT   METAL       468    468       Iron (heme axial ligand).
FT                                {ECO:0000250|UniProtKB:P24464}.
FT   BINDING     328    328       Heme (covalent; via 1 link).
FT                                {ECO:0000250|UniProtKB:P24464}.
FT   VAR_SEQ       1    149       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_055578.
FT   VAR_SEQ     307    339       DEDGKKLSDEDIRAEADTFMFEGHDTTASGLSW -> AMTP
FT                                RPVVSPGSCTTLQSTQNTRSAAGRRCKNF (in isoform
FT                                2). {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_055579.
FT   VAR_SEQ     340    520       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_055580.
FT   VARIANT       7      7       S -> Y (in dbSNP:rs3093104).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_013116.
FT   VARIANT      12     12       W -> G (in dbSNP:rs3093105).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:9799565,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_013117.
FT   VARIANT     185    185       G -> V (in dbSNP:rs3093153).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_013118.
FT   VARIANT     269    269       A -> D (in dbSNP:rs1805040).
FT                                /FTId=VAR_020125.
FT   VARIANT     433    433       V -> M (polymorphism probably associated
FT                                with CMRES; increases warfarin
FT                                maintenance dose in patients on warfarin
FT                                anti-coagulant therapy, possibly due to
FT                                increased hepatic vitamin K levels that
FT                                warfarin must antagonize. Decreased
FT                                phylloquinone omega-hydroxylase activity.
FT                                Decreased production of 20-
FT                                hydroxyeicosatetraenoic acid (20-HETE);
FT                                dbSNP:rs2108622).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:17341693,
FT                                ECO:0000269|PubMed:18250228,
FT                                ECO:0000269|PubMed:18574070,
FT                                ECO:0000269|PubMed:19207028,
FT                                ECO:0000269|PubMed:19270263,
FT                                ECO:0000269|PubMed:19297519,
FT                                ECO:0000269|PubMed:20555338,
FT                                ECO:0000269|PubMed:23132553,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_013119.
FT   VARIANT     519    519       L -> M (in dbSNP:rs3093200).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_013120.
FT   CONFLICT     12     13       WP -> CR (in Ref. 3; AAC50052 and 9;
FT                                AAF86378). {ECO:0000305}.
FT   CONFLICT     25     25       V -> A (in Ref. 8; AAH67437).
FT                                {ECO:0000305}.
FT   CONFLICT    169    169       E -> D (in Ref. 8; AAH67440).
FT                                {ECO:0000305}.
FT   CONFLICT    336    336       G -> V (in Ref. 3; AAC50052).
FT                                {ECO:0000305}.
FT   CONFLICT    391    391       L -> V (in Ref. 3; AAC50052).
FT                                {ECO:0000305}.
SQ   SEQUENCE   520 AA;  59853 MW;  1791F9E6EECB59B5 CRC64;
     MSQLSLSWLG LWPVAASPWL LLLLVGASWL LAHVLAWTYA FYDNCRRLRC FPQPPRRNWF
     WGHQGMVNPT EEGMRVLTQL VATYPQGFKV WMGPISPLLS LCHPDIIRSV INASAAIAPK
     DKFFYSFLEP WLGDGLLLSA GDKWSRHRRM LTPAFHFNIL KPYMKIFNES VNIMHAKWQL
     LASEGSACLD MFEHISLMTL DSLQKCVFSF DSHCQEKPSE YIAAILELSA LVSKRHHEIL
     LHIDFLYYLT PDGQRFRRAC RLVHDFTDAV IQERRRTLPS QGVDDFLQAK AKSKTLDFID
     VLLLSKDEDG KKLSDEDIRA EADTFMFEGH DTTASGLSWV LYHLAKHPEY QERCRQEVQE
     LLKDREPKEI EWDDLAHLPF LTMCMKESLR LHPPVPVISR HVTQDIVLPD GRVIPKGIIC
     LISVFGTHHN PAVWPDPEVY DPFRFDPENI KERSPLAFIP FSAGPRNCIG QTFAMAEMKV
     VLALTLLRFR VLPDHTEPRR KPELVLRAEG GLWLRVEPLS
//
